Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment

Trial Profile

Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Carboplatin (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GORTEC-ELANFIT
  • Most Recent Events

    • 23 Oct 2018 Planned End Date changed from 1 Dec 2019 to 1 Aug 2021.
    • 23 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 03 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top